Previous literatures reported that loss-of-function mutations in SPOP compromised ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumor-infiltrating lymphocytes in mouse tumors and in primary human prostate cancer specimens 14. The gene discussed is SPOP; the disease is neoplasm.